AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology - Insider Monkey

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best Canadian stocks with huge upside potential. Earlier in May, AbCellera Biologics announced that the US Court of Appeals for the Federal Circuit/CAFC issued a Rule 36 Order, which affirmed the validity of its US Patent No. 10,087,408 (“the ‘408 Patent”). The patent specifically covers microfluidic devices and their application in culturing and selectively recovering cells.

Previously, Bruker Cellular Analysis Inc., which is a subsidiary of Bruker Corporation (NASDAQ:BRKR), had challenged the claims of the ‘408 Patent. Bruker argued for the patent’s invalidity based on allegations of anticipation and obviousness in light of prior art. However, the US Patent Trial and Appeal Board/PTAB rejected all of Bruker’s arguments. The CAFC’s recent decision further confirms the validity of all claims within AbCellera’s ‘408 Patent.

A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform.

The 408 Patent is an integral part of ongoing multi-patent infringement litigation between AbCellera and Bruker, which is currently pending in the US District Court for the Northern District of California. AbCellera intends to continue defending its intellectual property portfolio and looks forward to proving its infringement case against Bruker in the District Court.

AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines for indications with unmet medical needs in the US. Bruker Corporation (NASDAQ:BRKR) develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions.

While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

NASDAQ:ABCLNASDAQ:BRKRYahoo FinanceBruker Corporation (NASDAQ:BRKR)AbCellera Biologics Inc. (NASDAQ:ABCL)

Returns since its inception in May 2014 (through February 19th, 2025)

Warren Buffett

Berkshire Hathaway

$293,447,417,000

David Einhorn

Greenlight Capital

$1,491,303,000

George Soros

Soros Fund Management

$5,416,602,000

Jim Simons

Renaissance Technologies

$77,426,184,000

Leon Cooperman

Omega Advisors

$1,886,381,000

Carl Icahn

Icahn Capital LP

$22,521,664,000

Steve Cohen

Point72 Asset Management

$22,767,998,000

John Paulson

Paulson & Co

$3,510,256,000

David Tepper

Appaloosa Management LP

$4,198,712,000

Paul Tudor Jones

Tudor Investment Corp

$6,160,740,000